



April 30, 2026

FOR IMMEDIATE RELEASE

Company name	Resorttrust, Inc.
Representative	Ariyoshi Fushimi, CEO and Representative Director
Code	4681, Prime of Tokyo Stock Exchange and Premier of Nagoya Stock Exchange

**CICS, Inc. (a consolidated subsidiary of Resorttrust, Inc.) has submitted a medical device marketing authorization application for the accelerator-based BNCT treatment system**

Resorttrust, Inc. (“the Company”) announces that Cancer Intelligence Care Systems, Inc., its consolidated subsidiary (“CICS,” President: Tetsuya Furukawa; Head Office: Koto-ku, Tokyo), has submitted a medical device marketing authorization application for the CICS-1 accelerator-based neutron irradiation device (“the Device”) used in boron neutron capture therapy (BNCT) on April 30, 2026. The application is based on the results of a domestic phase II clinical trial (the “Trial”) in patients with cutaneous angiosarcoma\*1.

The Trial was conducted at the National Cancer Center Hospital using the Device and STELLA PHARMA’s boron drug (SPM-011) in unresectable cutaneous angiosarcoma.

The Device has been designated as an “orphan medical device for rare diseases” for cutaneous angiosarcoma by Japan’s Ministry of Health, Labour and Welfare in 2023. As the Device is eligible for priority review, it is expected to be made available in clinical settings promptly. The impact of this matter on the Company’s consolidated financial results for the current fiscal year is expected to be minimal.

The Resorttrust Group entered the medical business in 1994 and began operating a membership-based comprehensive medical club. At the Yamanakako Clinic, Positron Emission Tomography (hereinafter “PET”), which was then a research-use device, was introduced for cancer screening, making a significant contribution to the widespread use of PET in Japan. Today, in addition to screening services, the Group is expanding its solutions in the field of treatment and also supports the operation of facilities providing advanced cancer immunotherapy. In addition, under its brand identity “Together for a Wonderful Life,” the Group has been driven by the desire to create a society where no one loses a loved one to cancer and involved in cancer screening and treatment. The Group aims to bring new hope to cancer treatment both in Japan and across Asia.

\*1: Angiosarcoma

Angiosarcoma is a type of cancer that originates from the endothelial cells of blood vessels. It can occur throughout the body,

most commonly in the skin. It is considered to be very rare and highly malignant, and no effective standard treatment has been established.

### About BNCT


Boron neutron capture therapy (BNCT), a form of radiotherapy, is a new method of treating cancer. When patients receive a boron agent, a boron compound ( $^{10}\text{B}$ ) accumulates in their cancer cells. The area of the tumor is then exposed to an external source of extremely low-energy neutron radiation, which while having little effect on the human body, causes the boron ( $^{10}\text{B}$ ) to capture neutrons, resulting in a reaction that causes the release of alpha rays and  $^7\text{Li}$  nuclei. BNCT is therefore a medical treatment that leverages radiation to selectively kill cancer cells. In addition, in principle, as treatment is completed with a single neutron irradiation, expectations are for this to be a treatment that causes little damage to the body.

### About CICS-1

CICS-1 is an accelerator-based neutron capture therapy device jointly developed by CICS and the National Cancer Center Hospital. It generates neutrons by accelerating protons using an RFQ (radio-frequency quadrupole) linear accelerator and colliding them with a lithium target. A key feature of this system is the minimal inclusion of fast neutrons, which can have significant harmful effects on the human body.

In addition, because the energy of the generated neutrons is 800 keV or lower, the system allows for downsizing of the moderation setup needed to slow the neutrons down to around 10 keV, the energy level suitable for BNCT.

Unlike existing devices that irradiate neutrons horizontally to patients, the device developed by CICS can irradiate vertically, making it potentially applicable to conditions that were previously difficult to treat.



CICS-1



BNCT irradiation room at the National Cancer Center

Hospital